reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra 
Welcome,         Profile    Billing    Logout  
 4 Diseases   0 Trials   0 Trials   302 News 


12»
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease (clinicaltrials.gov) -  Jun 14, 2024   
    P3,  N=132, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Dec 2024 --> Jun 2024
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease (clinicaltrials.gov) -  Oct 26, 2022   
    P2,  N=63, Completed, 
    Recruiting --> Completed | N=525 --> 757 | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022 Recruiting --> Completed | Trial completion date: Oct 2022 --> May 2022 | Trial primary completion date: Oct 2022 --> May 2022
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease (clinicaltrials.gov) -  Aug 3, 2022   
    P3,  N=361, Completed, 
    Recruiting --> Completed | Trial completion date: Oct 2022 --> May 2022 | Trial primary completion date: Oct 2022 --> May 2022 Recruiting --> Completed | Trial completion date: Jun 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Mar 2022
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease (clinicaltrials.gov) -  May 23, 2022   
    P2,  N=56, Completed, 
    Recruiting --> Completed | Trial completion date: Jun 2022 --> Mar 2022 | Trial primary completion date: Jun 2022 --> Mar 2022 Recruiting --> Completed | Trial completion date: Apr 2022 --> Oct 2021 | Trial primary completion date: Apr 2022 --> Oct 2021
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    The Novel RASP Modulator Reproxalap Rapidly Improves Signs and Symptoms of Dry Eye Disease: The TRANQUILITY Run-In Cohort (WEWCC - Level 1, 144B) -  Apr 26, 2022 - Abstract #ASCRSASOA2022ASCRS-ASOA_1082;    
    The most common adverse event in drug-treated subjects was transient and mild instillation site discomfort. Conclusion Against a backdrop of current topical non-corticosteroid ocular therapies that require weeks to evidence activity, reproxalap may represent a novel, rapidly acting option for patients suffering from dry eye disease.
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease (clinicaltrials.gov) -  Mar 29, 2022   
    P2/3,  N=331, Completed, 
    Conclusion Against a backdrop of current topical non-corticosteroid ocular therapies that require weeks to evidence activity, reproxalap may represent a novel, rapidly acting option for patients suffering from dry eye disease. Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Sep 2021
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion, Trial completion date, Trial primary completion date:  A Clinical Trial to Assess Subjects With Dry Eye Disease. (clinicaltrials.gov) -  Dec 9, 2021   
    P2,  N=158, Completed, 
    Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Sep 2021
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion date, Trial primary completion date:  A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis (clinicaltrials.gov) -  Dec 20, 2019   
    P1/2,  N=52, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Nov 2019 | Trial primary completion date: Apr 2020 --> Nov 2019 Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion date, Trial primary completion date:  SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. (clinicaltrials.gov) -  Mar 19, 2019   
    P3,  N=100, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion:  ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis (clinicaltrials.gov) -  Jan 9, 2019   
    P3,  N=318, Completed, 
    Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Recruiting --> Completed
  • ||||||||||  reproxalap ophthalmic (ADX-102 ophthalmic) / Aldeyra
    Trial completion:  A Study of ADX-102 in Subjects With Allergic Conjunctivitis (clinicaltrials.gov) -  Jul 11, 2017   
    P2,  N=150, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed